Eravacycline

Indications

Eravacycline is an antibacterial agent belonging to the tetracycline class. It is specifically indicated for the treatment of complicated intra-abdominal infections in adults aged 18 and over.

Pharmacodynamics

Eravacycline operates by disrupting bacterial protein synthesis, thereby effectively targeting and treating complicated intra-abdominal infections. This mechanism enables it to combat a wide range of bacteria responsible for such infections.

Absorption

Following a single-dose intravenous administration, eravacycline exhibits dose-proportional increases in both the area under the curve (AUC) and maximum concentration (Cmax) for doses ranging from 1 mg/kg to 3 mg/kg, which is three times the approved dose. Furthermore, after intravenous administration of 1 mg/kg every 12 hours, there is approximately a 45% accumulation of the drug.

Metabolism

Eravacycline is primarily metabolized through oxidation, a process mediated by cytochrome P450 3A4 (CYP3A4) and flavin-containing monooxygenase (FMO) enzymes.

Mechanism of Action

Eravacycline is classified as a fluorocycline antibacterial agent within the tetracycline class of antimicrobial drugs. It functions by interfering with bacterial protein synthesis. Specifically, eravacycline binds to the 30S ribosomal subunit, thereby obstructing the addition of amino acid residues into the elongating peptide chains. Generally, eravacycline exhibits a bacteriostatic effect on gram-positive bacteria, such as Staphylococcus aureus and Enterococcus faecalis. Notably, it has demonstrated bactericidal activity in vitro against particular strains of Escherichia coli and Klebsiella pneumoniae.